An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)

A Phase 2, Open-Label Extension, Efficacy and Safety Study of a Retinoic Acid Receptor Gamma (RARγ) Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by heterotopic ossification (HO), i.e., abnormal bone formation, often associated with painful, recurrent episodes of soft tissue swelling (flare-ups). Lesions begin in early childhood and lead to progressive ankyloses of major joints with resultant loss of movement.

In this study, the ability of different palovarotene dosing regimens to prevent the formation of new HO will be evaluated in adult and pediatric participants with FOP.

Study Overview

• Status: Completed
• Conditions: Fibrodysplasia Ossificans Progressiva
• Intervention / Treatment: Drug: Palovarotene dose level 1; Drug: Palovarotene dose level 2; Drug: Palovarotene dose level 3; Drug: Palovarotene dose level 4

Detailed Description

The main objective of this Phase 2, multicenter, open-label study is to evaluate the safety and efficacy of different palovarotene dosing regimens in participants with FOP. Efficacy will be assessed based on the ability of palovarotene to prevent the formation of new heterotopic ossification (HO) as assessed by low-dose whole body computed tomography (WBCT) scan, excluding head.

The study was divided into four parts: Part A (completed on July 2017), Part B (completed on October 2018), Part C (completed) and Part D (completd). Each part was associated with revised palovarotene treatment regimens.

In Part A, all pediatric and adult participants who successfully completed Study PVO-1A-201 were enrolled and followed for up to 36 months. Participants who had an eligible flare-up received 10 mg palovarotene daily for 14 days, followed by 5 mg palovarotene daily for 28 days (or weight-based equivalent).

In Part B, participants who successfully completed Study PVO-1A-201 (including any participant who participated in Part A of Study PVO-1A-202) as well as up to 20 new adult participants were followed for up to 24 months. The Adult Cohort included all participants with at least 90% skeletal maturity, regardless of age. The Pediatric Cohort included all participants with less than 90% skeletal maturity. Any Pediatric Cohort participant who achieved ≥90% skeletal maturity during Part B was considered for enrollment into the Adult Cohort at the discretion of the Investigator. Part B added a 5 mg palovarotene daily chronic treatment regimen administered between flare-ups for participants in the Adult Cohort for up to 24 months. Part B also increased the flare-up dosing to 20 mg palovarotene daily for 28 days, followed by 10 mg palovarotene daily for 56 days (or weight-adjusted equivalents in the Pediatric Cohort). Treatment could be extended if the flare-up was still ongoing.

In Part C, participants from Part B are being followed for up to an additional 48 months. There will be no new participants in Part C. All eligible participants, including skeletally immature participants, are receiving 5 mg palovarotene daily chronic treatment regimen (weight-adjusted doses for skeletally immature participants).

In Part D, annual post last dose of study treatment assessments for up to 2 years will be obtained in participants who were skeletally immature at the time of study treatment discontinuation in order to obtain longer-term safety data. No new participants will be enrolled into Part D.

Part C plus Part D duration will not exceed 48 months.

All participants will undergo all study procedures as specified in the respective schedule of assessments and for as long as they are not 100% skeletally mature.

• Study Type: Interventional
• Enrollment (Actual): 54
• Phase: Phase 2

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina
    • Hospital Italiano de Buenos Aires, Department of Pediatrics
• Australia
  • Queensland
    • Woolloongabba, Queensland, Australia, 4102
      • Queensland University of Technology (QUT) Institute of Health and Biomedical Innovation (IHBI)
• France
  • Paris, France
    • Hôpital Necker-Enfants Malades, Department of Genetics
• United Kingdom
  • Middlesex
    • Stanmore, Middlesex, United Kingdom, HA7 4LP
      • The Royal National Orthopaedic Hospital, Brockley Hill
• United States
  • California
    • San Francisco, California, United States, 94143
      • University of California San Francisco, Division of Endocrinology and Metabolism
  • Minnesota
    • Rochester, Minnesota, United States, 55905
      • Mayo Clinic, Department of Medicine
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19104
      • University of Pennsylvania, Center for FOP & Related Bone Disorders

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 years to 65 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Completion of Study PVO-1A-202/Part B.
• Written, signed, and dated informed consent and, for participants who are minors, age-appropriate participant assent (performed according to local regulations).
• Accessible for treatment with palovarotene and follow-up (able and willing to travel to a site for the initial and all follow-up clinic visits).
• Able to undergo low-dose, WBCT scan, excluding head.
• Females of child-bearing potential must have a negative blood or urine pregnancy test (with sensitivity of at least 50 mIU/mL) prior to administration of palovarotene.
• Male and FOCBP participants must agree to remain abstinent from heterosexual sex during treatment and for 1 month after treatment or, if sexually active, to use two effective methods of birth control during and for 1 month after treatment. Additionally, sexually active females of childbearing potential (FOCBP) participants must already be using two effective methods of birth control 1 month before treatment is to start. Specific risk of the use of retinoids during pregnancy, and the agreement to remain abstinent or use two effective methods of birth control will be clearly defined in the informed consent and the participant or legally authorized representatives.

Exclusion Criteria:

• Any reason that, in the opinion of the Investigator, would lead to the inability of the participant and/or family to comply with the protocol.
• Amylase or lipase >2x above the upper limit of normal or with a history of pancreatitis.
• Elevated aspartate aminotransferase or alanine aminotransferase >2.5x the upper limit of normal.
• Fasting triglycerides >400 mg/dL with or without therapy.
• Currently using vitamin A or beta carotene, multivitamins containing vitamin A or beta carotene, herbal preparations containing vitamin A or beta carotene, or fish oil, and unable or unwilling to discontinue use of these products during palovarotene treatment.
• Participants experiencing suicidal ideation (type 4 or 5) or any suicidal behavior within the past month as defined by the Columbia Suicide Severity Rating Scale (C-SSRS).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Palovarotene dose level 1 (completed); Participants received 10 mg palovarotene for 14 days, followed by 5 mg palovarotene for 28 days (or weight-based equivalent) for eligible flare-ups (Part A).	Drug: Palovarotene dose level 1; Palovarotene was taken orally once daily at approximately the same time each day.
Experimental: Palovarotene dose level 2; Participants with at least 90% skeletal maturity received 5 mg palovarotene for up to 24 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).	Drug: Palovarotene dose level 2; Palovarotene will be taken orally once daily at approximately the same time each day.
Experimental: Palovarotene dose level 3; Participants with less than 90% skeletal maturity received weight-adjusted doses of 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).	Drug: Palovarotene dose level 3; Palovarotene will be taken orally once daily at approximately the same time each day.
Experimental: Palovarotene dose level 4; All participants will receive 5 mg palovarotene for up to 48 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part C). Skeletally immature participants will receive weight-adjusted doses.	Drug: Palovarotene dose level 4; Palovarotene will be taken orally once daily at approximately the same time each day.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part A and Part B - Proportion of flare-up with no new HO ("responders")	Assessed by computed tomography (CT) scan (or plain radiographs for participants unable to undergo CT scan)	Week 12
Part C - Annualized change in new HO volume	Assessed by low-dose whole body computed tomography (WBCT) (excluding head)	Every 12 months for up to 72 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part A - Proportion of participants across the seven HO scores (0-6)	Assessed by plain radiographs	Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 6 and 12 (Flare-up Component)
Part A - Change from baseline in amount (area) of new heterotopic bone formed	Assessed by plain radiographs	Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 6 and 12 (Flare-up Component)
Part A - Change from baseline in cartilage, bone, angiogenesis, and inflammation biomarkers		Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 2, 4, 6, and 12 (Flare-up Component)
Part A and Part B - Change from baseline in active range of motion (ROM)	Assessed by goniometer	Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 6 and 12 (Flare-up Component)
Part A and Part B - Change from baseline in ROM	Assessed by Cumulative Analogue Joint Involvement Scale (CAJIS)	Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 6 and 12 (Flare-up Component)
Part A and Part B - Participant and Investigator global assessment of movement		Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 6 and 12 (Flare-up Component)
Part A - Change from baseline in pain and swelling (for participants under 8 years of age)	Assessed by numeric rating scale (NRS) or Faces Pain Scale-Revised (FPS-R)	Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 2, 4, 6, 9, and 12 (Flare-up Component)
Part A and Part B - Change from baseline in physical function	Assessed by age-appropriate forms of the FOP-Physical Function Questionnaire (FOP-PFQ)	Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 2, 4, 6, 8, 9, and 12 (Flare-up Component)
Part A and Part B - Change from baseline in physical and mental health	Assessed by age-appropriate forms of the Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale	Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 2, 4, 6, 8, 9, and 12 (Flare-up Component)
Part A and Part B - Change from baseline in the use of assistive devices and adaptations for daily living by FOP participants		Study Months 6 and 12 (Follow-up Component); Flare-up Weeks 6 and 12 (Flare-up Component)
Part A and Part B - Presence of soft tissue swelling and/or cartilage	Assessed by magnetic resonance imaging (MRI) (or by US in participants unable to undergo MRI)	Flare-up Weeks 6 and 12 (Flare-up Component)
Part B - Change from baseline in amount of bone formation (volume)	Assessed by low-dose CT scan (or area by plain radiographs for participants unable to undergo CT scan)	Flare-up Week 12
Part B - Change from baseline in cartilage, bone, angiogenesis, and inflammation biomarkers		Flare-up Weeks 4, 8, and 12
Duration of active, symptomatic flare-up (start date and end date)	Assessed by the participant and the Investigator	Up to 12 weeks
Part B (Chronic treatment) - Change from baseline in whole body burden of HO	Assessed by low-dose WBCT scan (excluding head)	Study Months 12 and 24
Part B (Chronic treatment) - Number of flare-ups per participant-month overall, and by edema severity		Up to 24 months
Part C - Percent of participants with new HO		Every 12 months up to 72 months
Part C - Change from baseline in ROM	Assessed by CAJIS	Every 6 months up to 72 months
Part C - Change from baseline in physical function	Assessed by age-appropriate forms of the FOP-PFQ	Every 6 months up to 72 months
Part C - Change from baseline in physical and mental function for participants ≥15 years old and mental function for participants <15 years old	Assessed by age-appropriate forms of the PROMIS Global Health Scale	Every 6 months up to 72 months

Collaborators and Investigators

• Sponsor: Clementia Pharmaceuticals Inc.

Publications and helpful links

General Publications

• Shimono K, Tung WE, Macolino C, Chi AH, Didizian JH, Mundy C, Chandraratna RA, Mishina Y, Enomoto-Iwamoto M, Pacifici M, Iwamoto M. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-gamma agonists. Nat Med. 2011 Apr;17(4):454-60. doi: 10.1038/nm.2334. Epub 2011 Apr 3. Erratum In: Nat Med. 2012 Oct;18(10):1592.

Helpful Links

• Website for the International FOP Association
• Website for the French FOP Association
• Click here for more information about this study: A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects with Fibrodysplasia Ossificans Progressiva (FOP)

Study record dates

Study Major Dates

• Study Start (Actual): October 27, 2014
• Primary Completion (Actual): September 20, 2022
• Study Completion (Actual): September 20, 2022

Study Registration Dates

• First Submitted: October 26, 2014
• First Submitted That Met QC Criteria: October 28, 2014
• First Posted (Estimate): October 30, 2014

Study Record Updates

• Last Update Posted (Actual): October 14, 2022
• Last Update Submitted That Met QC Criteria: October 11, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Keywords: Efficacy and safety; Clinical trial Phase 2; Heterotopic ossification; Fibrodysplasia Ossificans Progressiva; Flare-up; Palovarotene; Retinoic acid receptor agonist; Retinoic acid receptor gamma agonist; Clementia; Myositis Ossificans Progressiva; Munchmeyer's Disease; FOP; Open-label extension study; Ipsen
• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Muscular Diseases; Myositis; Myositis Ossificans
• Other Study ID Numbers: PVO-1A-202; 2014-002496-28 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No